Related Experiment Video

Updated: Mar 30, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3

Nadège Gaborit1, Moshit Lindzen1, Yosef Yarden1

  • 1a Department of Biological Regulation , Weizmann Institute of Science , Rehovot , Israel.

Human Vaccines & Immunotherapeutics
|November 4, 2015
PubMed

Insights

The epidermal growth factor receptor (EGFR) family is crucial in cancer. Targeting HER3/ERBB3, a key player in drug resistance, shows promise for new anti-cancer therapies, especially in combination treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer progression involves oncogenic mutations and growth factors driving tumor growth, metastasis, and angiogenesis.
  • Approved anti-cancer drugs target the epidermal growth factor receptor (EGFR) and HER2/ERBB2.
  • The HER3/ERBB3 receptor is implicated in carcinoma resistance to various anti-cancer drugs.

Purpose of the Study:

  • To review current efforts and emerging strategies targeting the HER3/ERBB3 receptor.
  • To highlight the role of HER3/ERBB3 in drug resistance.
  • To emphasize drug combinations and unique biochemical features of HER3/ERBB3.

Main Methods:

  • Literature review of existing research on HER3/ERBB3.
  • Analysis of biochemical properties of HER3/ERBB3.
  • Examination of anti-HER3/ERBB3 agents and drug combinations.

Main Results:

  • HER3/ERBB3 plays a critical role in the development of drug resistance in carcinomas.
  • Emerging anti-HER3/ERBB3 agents, including antibodies, are under investigation.
  • Drug combinations involving anti-HER3/ERBB3 agents show potential for overcoming resistance.

Conclusions:

  • Targeting HER3/ERBB3 is a promising strategy to overcome cancer drug resistance.
  • Further research into anti-HER3/ERBB3 agents and their combinations is warranted.
  • Understanding the unique biochemical aspects of HER3/ERBB3 is crucial for developing effective therapies.
Keywords:
HER3/ERBB3anti-cancer drugsmonoclonal antibodiesreceptor tyrosine kinasesignal transduction

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K